{"entity":{"type":"insider","cik":"0001967150","url":"/insider/0001967150","json_url":"/insider/0001967150.json","name":"Lyssikatos Joseph P","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":60,"n_filings":36,"first":"2023-10-03","last":"2026-02-10","span_basis":"filed_date"},"name_variants":[{"name":"Lyssikatos Joseph P","source":"filing","n_filings":36,"first_seen":"2023-10-03","last_seen":"2026-02-10"}],"transactions":[{"id":5754268,"accession":"0001967150-26-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001967150-26-000003","line_url":"/filing/0001967150-26-000003#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":29.0438,"price_display":"29.04","price_state":"stated","total_value":145219.0,"total_display":"145,219.00","total_whole":"145,219","shares_owned_after":740188.0,"shares_owned_after_display":"740,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-06","filed_date":"2026-02-10","scope":"insider"},{"id":5902687,"accession":"0001967150-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001967150-26-000002","line_url":"/filing/0001967150-26-000002","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":26.754949425,"price_display":"26.75","price_state":"stated","total_value":535098.9885,"total_display":"535,098.99","total_whole":"535,099","shares_owned_after":745188.0,"shares_owned_after_display":"745,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-20","filed_date":"2026-01-22","scope":"insider","n_lines":2},{"id":6207351,"accession":"0001967150-26-000001","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001967150-26-000001","line_url":"/filing/0001967150-26-000001","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91198.0,"shares_display":"91,198","price_per_share":27.22184870720849,"price_display":"27.22","price_state":"stated","total_value":2482578.1584,"total_display":"2,482,578.16","total_whole":"2,482,578","shares_owned_after":765188.0,"shares_owned_after_display":"765,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-09","filed_date":"2026-01-12","scope":"insider","n_lines":2},{"id":6207335,"accession":"0001967150-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001967150-26-000001","line_url":"/filing/0001967150-26-000001","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41302.0,"shares_display":"41,302","price_per_share":24.052970500217906,"price_display":"24.05","price_state":"stated","total_value":993435.7876,"total_display":"993,435.79","total_whole":"993,436","shares_owned_after":856386.0,"shares_owned_after_display":"856,386","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-08","filed_date":"2026-01-12","scope":"insider","n_lines":2},{"id":4286075,"accession":"0001967150-25-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001967150-25-000008","line_url":"/filing/0001967150-25-000008#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":16.8412,"price_display":"16.84","price_state":"stated","total_value":84206.0,"total_display":"84,206.00","total_whole":"84,206","shares_owned_after":897688.0,"shares_owned_after_display":"897,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-19","filed_date":"2025-12-23","scope":"insider"},{"id":4563239,"accession":"0001967150-25-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001967150-25-000007","line_url":"/filing/0001967150-25-000007","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":22.332382592,"price_display":"22.33","price_state":"stated","total_value":279154.7824,"total_display":"279,154.78","total_whole":"279,155","shares_owned_after":903180.0,"shares_owned_after_display":"903,180","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-19","filed_date":"2025-11-21","scope":"insider","n_lines":2},{"id":4607281,"accession":"0001967150-25-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001967150-25-000006","line_url":"/filing/0001967150-25-000006#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":22.082,"price_display":"22.08","price_state":"stated","total_value":276025.0,"total_display":"276,025.00","total_whole":"276,025","shares_owned_after":915188.0,"shares_owned_after_display":"915,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-20","filed_date":"2025-10-22","scope":"insider"},{"id":4973235,"accession":"0001967150-25-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001967150-25-000005","line_url":"/filing/0001967150-25-000005#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":20.2513,"price_display":"20.25","price_state":"stated","total_value":81005.2,"total_display":"81,005.20","total_whole":"81,005","shares_owned_after":927688.0,"shares_owned_after_display":"927,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-26","filed_date":"2025-09-30","scope":"insider"},{"id":4156884,"accession":"0001967150-25-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001967150-25-000004","line_url":"/filing/0001967150-25-000004#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":20.03,"price_display":"20.03","price_state":"stated","total_value":30045.0,"total_display":"30,045.00","total_whole":"30,045","shares_owned_after":931688.0,"shares_owned_after_display":"931,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-23","filed_date":"2025-09-25","scope":"insider"},{"id":4935727,"accession":"0001967150-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001967150-25-000003","line_url":"/filing/0001967150-25-000003","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":19.385335,"price_display":"19.39","price_state":"stated","total_value":135697.345,"total_display":"135,697.34","total_whole":"135,697","shares_owned_after":935318.0,"shares_owned_after_display":"935,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-19","filed_date":"2025-09-23","scope":"insider","n_lines":2},{"id":5125657,"accession":"0001415889-25-022648","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022648","line_url":"/filing/0001415889-25-022648#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":20.0132,"price_display":"20.01","price_state":"stated","total_value":150099.0,"total_display":"150,099.00","total_whole":"150,099","shares_owned_after":940188.0,"shares_owned_after_display":"940,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-21","filed_date":"2025-08-21","scope":"insider"},{"id":5125650,"accession":"0001415889-25-022648","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-022648","line_url":"/filing/0001415889-25-022648#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":19.6235,"price_display":"19.62","price_state":"stated","total_value":98117.5,"total_display":"98,117.50","total_whole":"98,118","shares_owned_after":947688.0,"shares_owned_after_display":"947,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-19","filed_date":"2025-08-21","scope":"insider"},{"id":5005255,"accession":"0001415889-25-020206","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-020206","line_url":"/filing/0001415889-25-020206","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":22.291664032,"price_display":"22.29","price_state":"stated","total_value":278645.8004,"total_display":"278,645.80","total_whole":"278,646","shares_owned_after":953264.0,"shares_owned_after_display":"953,264","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-21","filed_date":"2025-07-23","scope":"insider","n_lines":2},{"id":4920211,"accession":"0001415889-25-018116","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-018116","line_url":"/filing/0001415889-25-018116#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":21.3966,"price_display":"21.40","price_state":"stated","total_value":267457.5,"total_display":"267,457.50","total_whole":"267,458","shares_owned_after":965188.0,"shares_owned_after_display":"965,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-20","filed_date":"2025-06-24","scope":"insider"},{"id":5123324,"accession":"0001415889-25-015787","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-015787","line_url":"/filing/0001415889-25-015787#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":20.0293,"price_display":"20.03","price_state":"stated","total_value":150219.75,"total_display":"150,219.75","total_whole":"150,220","shares_owned_after":977688.0,"shares_owned_after_display":"977,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-03","filed_date":"2025-06-05","scope":"insider"},{"id":4556814,"accession":"0001415889-25-013993","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-013993","line_url":"/filing/0001415889-25-013993#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":16.3067,"price_display":"16.31","price_state":"stated","total_value":81533.5,"total_display":"81,533.50","total_whole":"81,534","shares_owned_after":985188.0,"shares_owned_after_display":"985,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-19","filed_date":"2025-05-21","scope":"insider"},{"id":5039290,"accession":"0001415889-25-012031","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012031","line_url":"/filing/0001415889-25-012031#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2470.0,"shares_display":"2,470","price_per_share":20.0099,"price_display":"20.01","price_state":"stated","total_value":49424.453,"total_display":"49,424.45","total_whole":"49,424","shares_owned_after":990188.0,"shares_owned_after_display":"990,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-02","filed_date":"2025-05-05","scope":"insider"},{"id":5039284,"accession":"0001415889-25-012031","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-012031","line_url":"/filing/0001415889-25-012031#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5030.0,"shares_display":"5,030","price_per_share":20.0728,"price_display":"20.07","price_state":"stated","total_value":100966.184,"total_display":"100,966.18","total_whole":"100,966","shares_owned_after":992658.0,"shares_owned_after_display":"992,658","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-01","filed_date":"2025-05-05","scope":"insider"},{"id":5039224,"accession":"0001415889-25-011213","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-011213","line_url":"/filing/0001415889-25-011213","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":16.0731644,"price_display":"16.07","price_state":"stated","total_value":80365.822,"total_display":"80,365.82","total_whole":"80,366","shares_owned_after":998018.0,"shares_owned_after_display":"998,018","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-04-21","filed_date":"2025-04-23","scope":"insider","n_lines":2},{"id":4466856,"accession":"0001415889-25-008790","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-008790","line_url":"/filing/0001415889-25-008790#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":20.606,"price_display":"20.61","price_state":"stated","total_value":257575.0,"total_display":"257,575.00","total_whole":"257,575","shares_owned_after":1002688.0,"shares_owned_after_display":"1,002,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-19","filed_date":"2025-03-21","scope":"insider"},{"id":2486314,"accession":"0001415889-24-025504","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-025504","line_url":"/filing/0001415889-24-025504#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":847.0,"shares_display":"847","price_per_share":30.003,"price_display":"30.00","price_state":"stated","total_value":25412.541,"total_display":"25,412.54","total_whole":"25,413","shares_owned_after":1015188.0,"shares_owned_after_display":"1,015,188","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-22","scope":"insider"},{"id":2044202,"accession":"0001415889-24-024992","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-024992","line_url":"/filing/0001415889-24-024992","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37878.0,"shares_display":"37,878","price_per_share":28.15780062833307,"price_display":"28.16","price_state":"stated","total_value":1066561.1722,"total_display":"1,066,561.17","total_whole":"1,066,561","shares_owned_after":1019624.0,"shares_owned_after_display":"1,019,624","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-09","filed_date":"2024-10-10","scope":"insider","n_lines":2},{"id":2044193,"accession":"0001415889-24-024992","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024992","line_url":"/filing/0001415889-24-024992","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13267.0,"shares_display":"13,267","price_per_share":27.965932056983494,"price_display":"27.97","price_state":"stated","total_value":371024.0206,"total_display":"371,024.02","total_whole":"371,024","shares_owned_after":1054013.0,"shares_owned_after_display":"1,054,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-08","filed_date":"2024-10-10","scope":"insider","n_lines":2},{"id":2954458,"accession":"0001415889-24-024902","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024902","line_url":"/filing/0001415889-24-024902#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2707.0,"shares_display":"2,707","price_per_share":27.6051,"price_display":"27.61","price_state":"stated","total_value":74727.0057,"total_display":"74,727.01","total_whole":"74,727","shares_owned_after":1067180.0,"shares_owned_after_display":"1,067,180","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-07","filed_date":"2024-10-08","scope":"insider"},{"id":2954454,"accession":"0001415889-24-024902","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-024902","line_url":"/filing/0001415889-24-024902#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7522.0,"shares_display":"7,522","price_per_share":27.5109,"price_display":"27.51","price_state":"stated","total_value":206936.9898,"total_display":"206,936.99","total_whole":"206,937","shares_owned_after":1069887.0,"shares_owned_after_display":"1,069,887","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider"},{"id":2530791,"accession":"0001415889-24-024672","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-024672","line_url":"/filing/0001415889-24-024672#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":527.0,"shares_display":"527","price_per_share":27.5372,"price_display":"27.54","price_state":"stated","total_value":14512.1044,"total_display":"14,512.10","total_whole":"14,512","shares_owned_after":1077409.0,"shares_owned_after_display":"1,077,409","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-01","filed_date":"2024-10-03","scope":"insider"},{"id":2156593,"accession":"0001415889-24-022704","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-022704","line_url":"/filing/0001415889-24-022704","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":22.486782083333335,"price_display":"22.49","price_state":"stated","total_value":269841.385,"total_display":"269,841.38","total_whole":"269,841","shares_owned_after":1077986.0,"shares_owned_after_display":"1,077,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-29","filed_date":"2024-09-03","scope":"insider","n_lines":2},{"id":2806976,"accession":"0001415889-24-020688","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-020688","line_url":"/filing/0001415889-24-020688#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3099.0,"shares_display":"3,099","price_per_share":27.5571,"price_display":"27.56","price_state":"stated","total_value":85399.4529,"total_display":"85,399.45","total_whole":"85,399","shares_owned_after":1089936.0,"shares_owned_after_display":"1,089,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-31","filed_date":"2024-08-02","scope":"insider"},{"id":3000296,"accession":"0001415889-24-020476","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-020476","line_url":"/filing/0001415889-24-020476","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":26.698150283333334,"price_display":"26.70","price_state":"stated","total_value":320377.8034,"total_display":"320,377.80","total_whole":"320,378","shares_owned_after":1093238.0,"shares_owned_after_display":"1,093,238","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-29","filed_date":"2024-07-31","scope":"insider","n_lines":2},{"id":2043794,"accession":"0001415889-24-019202","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-019202","line_url":"/filing/0001415889-24-019202#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF SCIENTIFIC OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":22.8947,"price_display":"22.89","price_state":"stated","total_value":274736.4,"total_display":"274,736.40","total_whole":"274,736","shares_owned_after":1105035.0,"shares_owned_after_display":"1,105,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-01","filed_date":"2024-07-03","scope":"insider"},{"id":3262643,"accession":"0001415889-24-015031","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-015031","line_url":"/filing/0001415889-24-015031","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":21.733344633333335,"price_display":"21.73","price_state":"stated","total_value":260800.1356,"total_display":"260,800.14","total_whole":"260,800","shares_owned_after":2123.0,"shares_owned_after_display":"2,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-29","filed_date":"2024-05-31","scope":"insider","n_lines":2},{"id":2484967,"accession":"0001415889-24-011915","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-011915","line_url":"/filing/0001415889-24-011915","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":17.915645475,"price_display":"17.92","price_state":"stated","total_value":214987.7457,"total_display":"214,987.75","total_whole":"214,988","shares_owned_after":1013.0,"shares_owned_after_display":"1,013","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-29","filed_date":"2024-05-01","scope":"insider","n_lines":2},{"id":2222169,"accession":"0001415889-24-010830","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-010830","line_url":"/filing/0001415889-24-010830#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":25.0444,"price_display":"25.04","price_state":"stated","total_value":751332.0,"total_display":"751,332.00","total_whole":"751,332","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-11","filed_date":"2024-04-15","scope":"insider"},{"id":2563449,"accession":"0001415889-24-010228","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-010228","line_url":"/filing/0001415889-24-010228","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":18.595476233333333,"price_display":"18.60","price_state":"stated","total_value":223145.7148,"total_display":"223,145.71","total_whole":"223,146","shares_owned_after":71.0,"shares_owned_after_display":"71","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-01","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":2130588,"accession":"0001415889-24-006358","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-006358","line_url":"/filing/0001415889-24-006358#line-3","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001967150","owner_name":"Lyssikatos Joseph P","owner_display_name":"Lyssikatos Joseph P","owner_url":"/insider/0001967150","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF SCIENTIFIC OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10195.0,"shares_display":"10,195","price_per_share":16.2974,"price_display":"16.30","price_state":"stated","total_value":166151.993,"total_display":"166,151.99","total_whole":"166,152","shares_owned_after":1805.0,"shares_owned_after_display":"1,805","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-29","filed_date":"2024-03-04","scope":"insider"}],"collapsed":true,"next_cursor":"2024-02-29|2130588","ledger_fault":false,"count":{"value":60,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":60,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":60},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"Enliven Therapeutics, Inc.","url":"/issuer/0001672619","role":"Director, Officer (CHIEF SCIENTIFIC OFFICER)","n_filings":36,"first_seen":"2023-10-03","last_seen":"2026-02-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001967150","retrieved_at":"2026-08-25T06:45:49+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}